FI841128A - Pyrimidinderivat, deras framstaellning och deras anvaendning. - Google Patents

Pyrimidinderivat, deras framstaellning och deras anvaendning. Download PDF

Info

Publication number
FI841128A
FI841128A FI841128A FI841128A FI841128A FI 841128 A FI841128 A FI 841128A FI 841128 A FI841128 A FI 841128A FI 841128 A FI841128 A FI 841128A FI 841128 A FI841128 A FI 841128A
Authority
FI
Finland
Prior art keywords
deras
pyrimidinderivat
anvaendning
framstaellning och
och
Prior art date
Application number
FI841128A
Other languages
English (en)
Finnish (fi)
Other versions
FI841128A0 (fi
Inventor
Takao Takaya
Masayoshi Murata
Kiyotaka Ito
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB838308290A external-priority patent/GB8308290D0/en
Priority claimed from GB838315542A external-priority patent/GB8315542D0/en
Priority claimed from GB838327859A external-priority patent/GB8327859D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of FI841128A0 publication Critical patent/FI841128A0/fi
Publication of FI841128A publication Critical patent/FI841128A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI841128A 1983-03-25 1984-03-21 Pyrimidinderivat, deras framstaellning och deras anvaendning. FI841128A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB838308290A GB8308290D0 (en) 1983-03-25 1983-03-25 Pyrimidinone derivatives
GB838315542A GB8315542D0 (en) 1983-06-07 1983-06-07 Pyrimidinone derivatives
GB838327859A GB8327859D0 (en) 1983-10-18 1983-10-18 Pyrimidine derivatives

Publications (2)

Publication Number Publication Date
FI841128A0 FI841128A0 (fi) 1984-03-21
FI841128A true FI841128A (fi) 1984-09-26

Family

ID=27262023

Family Applications (1)

Application Number Title Priority Date Filing Date
FI841128A FI841128A (fi) 1983-03-25 1984-03-21 Pyrimidinderivat, deras framstaellning och deras anvaendning.

Country Status (13)

Country Link
US (3) US4612376A (fr)
EP (1) EP0123402B1 (fr)
KR (1) KR840008333A (fr)
CA (1) CA1256107A (fr)
DE (1) DE3473875D1 (fr)
DK (1) DK160492C (fr)
ES (2) ES8505972A1 (fr)
FI (1) FI841128A (fr)
GR (1) GR81758B (fr)
HU (1) HU195195B (fr)
NO (1) NO841168L (fr)
PH (1) PH22022A (fr)
SU (2) SU1349698A3 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent
US4598149A (en) * 1984-03-02 1986-07-01 Merck & Co., Inc. 3-amino-2-hydroxypropyl of pyrimidin-4-one useful as antihypertensive, cardioprotective, antiarrythmic, and antianginal agents
US4649142A (en) * 1984-06-25 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. 3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
US4708958A (en) * 1986-09-24 1987-11-24 G. D. Searle & Co. 6-(imidazolyphenyl)-4-iminopyrimidinones useful as hypotensive agents
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
IT1270122B (it) * 1994-10-04 1997-04-28 Ist Superiore Sanita 6-benzil-4-ossopirimidine sostituite, processo per la loro preparazione e composizioni farmaceutiche che le contengono
US6244121B1 (en) * 1998-03-06 2001-06-12 Applied Materials, Inc. Sensor device for non-intrusive diagnosis of a semiconductor processing system
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2005007658A2 (fr) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Derives aryle et heteroaryle condenses utilises comme modulateurs du metabolisme et prophylaxie et traitement des troubles metaboliques
DOP2006000009A (es) 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
US7776870B2 (en) 2005-08-22 2010-08-17 Melior Pharmaceuticals I, Inc. Methods for modulating Lyn kinase activity and treating related disorders
CA2678813A1 (fr) * 2007-02-20 2008-08-28 Melior Pharmaceuticals I, Inc. Procedes d'identification d'activateurs de lyn kinase
CA2693809A1 (fr) * 2007-07-23 2009-01-29 Melior Discovery, Inc. Procedes d'activation de irs-1 et akt
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
TWI393716B (zh) * 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
EP3378854B1 (fr) 2010-01-27 2022-12-21 Arena Pharmaceuticals, Inc. Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels
WO2011150300A1 (fr) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prévention de la dégénérescence des cellules pancréatiques bêta
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
WO2016031987A1 (fr) * 2014-08-29 2016-03-03 国立大学法人東京大学 Dérivé de pyrimidone ayant une activité inhibitrice de l'autotaxine
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
BR112019021140A2 (pt) 2017-04-10 2020-05-19 Univ Louisiana State composição, método para reduzir os níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento, método de indução do bege de adipócitos ou prevenção da degeneração das células beta do pâncreas, e, ativador de lyn cinase e agonista de trpm8 para uso na redução dos níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento.
CN109053589A (zh) * 2018-09-30 2018-12-21 浙江师范大学 4-亚胺基四氢嘧啶-2-酮类化合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296371A (fr) * 1969-02-26 1972-11-15
AU1108070A (en) * 1969-03-06 1971-08-12 Imperial Chemical Industries Limited Pyrimidine derivatives
GB1336138A (en) * 1969-12-10 1973-11-07 Ici Ltd Process for the production of pyrimidine derivatives
US3923807A (en) * 1973-09-10 1975-12-02 Takeda Chemical Industries Ltd 6-Aminouracil derivatives
JPS5053381A (fr) * 1973-09-20 1975-05-12
US4208366A (en) * 1978-10-31 1980-06-17 E. I. Du Pont De Nemours And Company Process for preparing a nonwoven web
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
US4612376A (en) * 1983-03-25 1986-09-16 Fujisawa Pharmaceutical Co., Ltd. Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent

Also Published As

Publication number Publication date
SU1349698A3 (ru) 1987-10-30
US4612376A (en) 1986-09-16
ES8601922A1 (es) 1985-11-01
DK166884A (da) 1984-09-26
HU195195B (en) 1988-04-28
ES530916A0 (es) 1985-06-16
US4746664A (en) 1988-05-24
DK160492B (da) 1991-03-18
CA1256107A (fr) 1989-06-20
SU1436872A3 (ru) 1988-11-07
GR81758B (fr) 1984-12-12
FI841128A0 (fi) 1984-03-21
ES8505972A1 (es) 1985-06-16
DK166884D0 (da) 1984-03-23
US4824851A (en) 1989-04-25
DK160492C (da) 1991-08-26
EP0123402B1 (fr) 1988-09-07
EP0123402A3 (en) 1985-09-18
DE3473875D1 (en) 1988-10-13
ES538190A0 (es) 1985-11-01
PH22022A (en) 1988-05-13
KR840008333A (ko) 1984-12-14
NO841168L (no) 1984-09-26
EP0123402A2 (fr) 1984-10-31

Similar Documents

Publication Publication Date Title
FI843594L (fi) Trihalogenmetylgrupper innehaollande karbonylmetylenheterocykler, foerfarande foer deras framstaellning och ljuskaenslig blandning vilken innehaoller dessa foereningar.
FI845038L (fi) Vattenloeslig, aminerad -1,3-bunden d-glukan och komposition innehaollande densamma.
FI77939B (fi) Askorbatstoerningsfri komposition, anordning och foerfarande foer bestaemning av peroxidativt aktiva substanser.
FI843403A0 (fi) Blandarmatur foer blandning av tvao vaetskor, saerskilt kallt och varmt vatten.
FI843856A0 (fi) 1-benzyl-aminoalkyl-pyrrolidinoner och deras syraadditionssalter, foerfarande foer deras framstaellning och laekemedel.
FI841128A (fi) Pyrimidinderivat, deras framstaellning och deras anvaendning.
FI842459A (fi) Tetrahydropyridazinonderivat, foerfaranden foer deras framstaellning och deras anvaendning.
FI843342A0 (fi) Anordning foer traening av benmuskulatur, cirkulation och armmuskulatur.
FI841841A (fi) 1-pyrimidinyloxi-3-hetarylalkylamino-2- propanoler, deras framstaellning och anvaendning.
FI844889L (fi) Foernaetade polymerater, foerfarande foer deras framstaellning och deras anvaendning.
FI840206A (fi) Aminosyraderivat, foerfarande foer deras framstaellning och anvaendning.
FI830032L (fi) Foerfarande och anordning foer bestaemmande av en oenskad centrallinje foer cylinderlika kroppar, saosom traestockar.
FI840428A (fi) Biologiskt aktivt ketonderivat, framstaellning och anvaendning.
FI842210A (fi) Kefalosporinester-derivat, deras framstaellning och anvaendning.
FI841479A (fi) Fenylalaninhydroxilas- cdna- kloner, foerfarande foer framstaellning av dessa och anvaendning av dessa foer diagnostisering av fenylketonuri.
FI841615A (fi) 4-fenyl-tetrahydro-furano-pyridiner, foerfarande foer deras framstaellning och farmaceutiska blandningar.
FI842845A (fi) Foerfarande och anordning foer styrning av omkopplarna i en flerfasig pulsvaexelriktare, isynnerhet i en transistorvaexelriktare.
FI844002A0 (fi) Stabiliserade, inerta organiska vaetskor innehaollande natriumditionitprodukter och deras anvaendning.
FI843825L (fi) Faergkatodstraolroer, komponent och framstaellningsmetod.
FI840843A (fi) Plasmider, foerfarande foer framstaellning av dessa, mikroorganismer innehaollande dessa och foerfaranden foer odling av mikroorganismerna.
FI843824A0 (fi) Faergkatodstraolroer, komponent och framstaellningsmetod.
FI842300A (fi) Mono- och ditioestrar, deras framstaellning och anvaendning.
FI843973L (fi) Foerfarande foer oeverfoering, saerskilt foer registrering och aotergivning av faergtelevisionssignaler.
FI844884L (fi) Akryltelomerer innehaollande medelst ljus tvaerbindande sidokedjor, syntes daerav och anvaendning av dessa foer belaeggning av metaller.
FI840587A (fi) Mjoeldryga-alkaloider, deras framstaellning och anvaendning.

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD.